KRMD Repro Med Systems Inc
Price (delayed)
$2.47
Market cap
$113.51M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.13
Enterprise value
$107.92M
Repro Med Systems, Inc. dba KORU Medical System develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM
Highlights
KRMD's EPS has surged by 57% year-on-year and by 48% since the previous quarter
The net income has surged by 56% year-on-year and by 49% since the previous quarter
The quick ratio has contracted by 38% YoY and by 2.7% from the previous quarter
The company's equity fell by 17% YoY and by 5% QoQ
Key stats
What are the main financial stats of KRMD
Market
Valuations
Earnings
Shares outstanding
45.96M
Market cap
$113.51M
Enterprise value
$107.92M
Price to earnings (P/E)
N/A
Price to book (P/B)
6.73
Price to sales (P/S)
3.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.21
Revenue
$33.65M
Gross profit
$21.33M
Operating income
-$6.45M
Net income
-$6.07M
EBIT
-$6.06M
EBITDA
-$5.18M
Free cash flow
-$1.61M
Per share
Balance sheet
Liquidity
EPS
-$0.13
EPS diluted
-$0.13
Free cash flow per share
-$0.04
Book value per share
$0.37
Revenue per share
$0.73
TBVPS
$0.58
Total assets
$27.22M
Total liabilities
$10.4M
Debt
$3.99M
Equity
$16.81M
Working capital
$11.93M
Debt to equity
0.24
Current ratio
2.66
Quick ratio
2.16
Net debt/EBITDA
1.08
Margins
Efficiency
Dividend
EBITDA margin
-15.4%
Gross margin
63.4%
Net margin
-18%
Operating margin
-19.2%
Return on assets
-22.2%
Return on equity
-33.5%
Return on invested capital
-40.7%
Return on capital employed
-30.3%
Return on sales
-18%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRMD stock price
How has the Repro Med Systems stock price performed over time
Intraday
-0.8%
1 week
8.81%
1 month
-10.83%
1 year
12.79%
YTD
-35.84%
QTD
-2.76%
Financial performance
How have Repro Med Systems's revenue and profit performed over time
Revenue
$33.65M
Gross profit
$21.33M
Operating income
-$6.45M
Net income
-$6.07M
Gross margin
63.4%
Net margin
-18%
KRMD's net margin has surged by 63% year-on-year and by 52% since the previous quarter
The net income has surged by 56% year-on-year and by 49% since the previous quarter
The company's operating margin rose by 47% YoY and by 13% QoQ
KRMD's operating income is up by 37% YoY and by 9% from the previous quarter
Growth
What is Repro Med Systems's growth rate over time
Valuation
What is Repro Med Systems stock price valuation
P/E
N/A
P/B
6.73
P/S
3.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.21
KRMD's EPS has surged by 57% year-on-year and by 48% since the previous quarter
KRMD's price to book (P/B) is 18% higher than its 5-year quarterly average of 5.7 but 9% lower than its last 4 quarters average of 7.4
The company's equity fell by 17% YoY and by 5% QoQ
The P/S is 47% below the 5-year quarterly average of 6.3 and 20% below the last 4 quarters average of 4.2
The revenue has grown by 18% YoY and by 5% from the previous quarter
Efficiency
How efficient is Repro Med Systems business performance
Repro Med Systems's return on assets has increased by 49% QoQ and by 44% YoY
KRMD's return on sales is up by 48% year-on-year and by 12% since the previous quarter
Repro Med Systems's ROE has increased by 47% from the previous quarter and by 36% YoY
KRMD's return on invested capital is up by 7% year-on-year and by 3.1% since the previous quarter
Dividends
What is KRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRMD.
Financial health
How did Repro Med Systems financials performed over time
The total assets is 162% more than the total liabilities
The current ratio has contracted by 42% YoY and by 11% from the previous quarter
The quick ratio has contracted by 38% YoY and by 2.7% from the previous quarter
KRMD's debt is 76% smaller than its equity
The company's equity fell by 17% YoY and by 5% QoQ
KRMD's debt is down by 10% year-on-year and by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.